Jeffrey W. Albers, Director at Blueprint Medicines Corp (BPMC), sold 43,861 shares at $85.22 ($3.8M) on 2024-03-20, disclosed to the SEC on 2024-03-22.
Scheduled sale ($3.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.22 | 2,730 | $233K | 6.1% |
| 2 | $85.22 | 2,730 | $233K | 6.1% |
| 3 | $86.46 | 6,251 | $540K | 14.1% |
| 4 | $86.46 | 6,251 | $540K | 14.1% |
| 5 | $87.26 | 8,440 | $736K | 19.3% |
| 6 | $87.26 | 8,440 |
| $736K |
| 19.3% |
| 7 | $88.60 | 6,285 | $557K | 14.6% |
| 8 | $89.12 | 1,367 | $122K | 3.2% |
| 9 | $89.12 | 1,367 | $122K | 3.2% |
| Total | $87.09 avg | 43,861 | $3.8M | 100% |
| Filing → |
| KYMR | SELL | 2025-10-14 | $296K | — | Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |